Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Opus Genetics to Participate in Leading Medical Conferences in May 2026
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Opus Genetics: Asymmetric Upside With LCA5 And BEST1
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Rating of “Buy” by Brokerages
Opus Genetics Announces $25 Million Private Placement
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of “Moderate Buy” from Analysts
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics to Participate in Upcoming Investment Conferences
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
Opus Genetics Announces $23 Million Registered Direct Offering
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice
Opus Genetics, Inc. - Special Call
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)